Today's Strong And Under The Radar Stock: IRadimed (IRMD)

Trade-Ideas LLC identified iRadimed (IRMD) as a strong and under the radar candidate
By TheStreet Wire ,

Trade-Ideas LLC identified

iRadimed

(

IRMD

) as a strong and under the radar candidate. In addition to specific proprietary factors, Trade-Ideas identified iRadimed as such a stock due to the following factors:

  • IRMD has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $3.7 million.
  • IRMD is making at least a new 3-day high.
  • IRMD has a PE ratio of 15.
  • IRMD is mentioned 1.32 times per day on StockTwits.
  • IRMD has not yet been mentioned on StockTwits today.
  • IRMD is currently in the upper 20% of its 1-year range.
  • IRMD is in the upper 35% of its 20-day range.
  • IRMD is in the upper 45% of its 5-day range.
  • IRMD is currently trading above yesterday's high.

'Strong and Under the Radar' stocks tend to be worthwhile stocks to watch for a variety of factors including historical back testing and price action. Market technicians refer to such stocks as being in an accumulation phase before a mark-up and peak. Traders and hedge funds have frequently found that these types of stocks continue to build a solid price base and then ultimately spike higher and peak when others 'discover' how good the stock is performing. By leveraging the social discovery aspect of StockTwits we are highlighting stocks that don't currently receive much attention from retail investors, but we suspect may soon garner more attention.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in IRMD with the Ticky from Trade-Ideas. See the FREE profile for IRMD NOW at Trade-Ideas

More details on IRMD:

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible products in the United States and internationally. IRMD has a PE ratio of 15. Currently there is 1 analyst that rates iRadimed a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for iRadimed has been 50,600 shares per day over the past 30 days. iRadimed has a market cap of $331.6 million and is part of the health care sector and health services industry. Shares are up 132.4% year-to-date as of the close of trading on Thursday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates iRadimed as a

hold

. The company's strengths can be seen in multiple areas, such as its notable return on equity, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the stock itself is trading at a premium valuation.

Highlights from the ratings report include:

  • In comparison to the other companies in the Health Care Equipment & Supplies industry and the overall market, IRADIMED CORP's return on equity significantly exceeds that of the industry average and is above that of the S&P 500.
  • IRMD's very impressive revenue growth greatly exceeded the industry average of 37.3%. Since the same quarter one year prior, revenues leaped by 114.9%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • IRMD has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 10.05, which clearly demonstrates the ability to cover short-term cash needs.
  • Powered by its strong earnings growth of 650.00% and other important driving factors, this stock has surged by 312.01% over the past year, outperforming the rise in the S&P 500 Index during the same period. Setting our sights on the months ahead, however, we feel that the stock's sharp appreciation over the last year has driven it to a price level which is now relatively expensive compared to the rest of its industry. The implication is that its reduced upside potential is not good enough to warrant further investment at this time.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Loading ...